206 related articles for article (PubMed ID: 31161844)
1. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.
Khadka RH; Sakemura R; Kenderian SS; Johnson AJ
Immunotherapy; 2019 Jul; 11(10):851-857. PubMed ID: 31161844
[No Abstract] [Full Text] [Related]
2. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
3. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
4. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
Cosenza M; Sacchi S; Pozzi S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299273
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.
Frey N; Porter D
Biol Blood Marrow Transplant; 2019 Apr; 25(4):e123-e127. PubMed ID: 30586620
[TBL] [Abstract][Full Text] [Related]
6. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
7. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
8. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.
Stein-Merlob AF; Ganatra S; Yang EH
Heart Fail Clin; 2022 Jul; 18(3):443-454. PubMed ID: 35718418
[TBL] [Abstract][Full Text] [Related]
9. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.
Shah D; Soper B; Shopland L
Front Immunol; 2023; 14():1190379. PubMed ID: 37304291
[TBL] [Abstract][Full Text] [Related]
10. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
Constantinescu C; Pasca S; Tat T; Teodorescu P; Vlad C; Iluta S; Dima D; Tomescu D; Scarlatescu E; Tanase A; Sigurjonsson OE; Colita A; Einsele H; Tomuleasa C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474415
[TBL] [Abstract][Full Text] [Related]
11. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome.
Liu Y; Fang Y; Chen X; Wang Z; Liang X; Zhang T; Liu M; Zhou N; Lv J; Tang K; Xie J; Gao Y; Cheng F; Zhou Y; Zhang Z; Hu Y; Zhang X; Gao Q; Zhang Y; Huang B
Sci Immunol; 2020 Jan; 5(43):. PubMed ID: 31953257
[TBL] [Abstract][Full Text] [Related]
12. Cytokine release syndrome.
Shimabukuro-Vornhagen A; Gödel P; Subklewe M; Stemmler HJ; Schlößer HA; Schlaak M; Kochanek M; Böll B; von Bergwelt-Baildon MS
J Immunother Cancer; 2018 Jun; 6(1):56. PubMed ID: 29907163
[TBL] [Abstract][Full Text] [Related]
13. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
Bachmann M
Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431
[TBL] [Abstract][Full Text] [Related]
14. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
Aldoss I; Khaled SK; Budde E; Stein AS
Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
[TBL] [Abstract][Full Text] [Related]
15. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.
Leclercq G; Steinhoff N; Haegel H; De Marco D; Bacac M; Klein C
Oncoimmunology; 2022; 11(1):2083479. PubMed ID: 35694193
[TBL] [Abstract][Full Text] [Related]
17. Management of T-Cell Engaging Immunotherapy Complications.
Varadarajan I; Lee DW
Cancer J; 2019; 25(3):223-230. PubMed ID: 31135530
[TBL] [Abstract][Full Text] [Related]
18. Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS).
Leclercq-Cohen G; Bacac M; Klein C
Expert Opin Biol Ther; 2023 Mar; 23(3):223-225. PubMed ID: 36629122
[No Abstract] [Full Text] [Related]
19. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
20. B-cell depleting immunotherapies: therapeutic opportunities and toxicities.
Del Bufalo F; Merli P; Alessi I; Locatelli F
Expert Rev Clin Immunol; 2019 May; 15(5):497-509. PubMed ID: 30681371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
